샘플 요청 목록

 카트 문의
시장보고서
상품코드
1888614

암 악액질 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 유형별, 유통 채널별, 지역별, 부문별 예측(2025-2033년)

Cancer Cachexia Market Size, Share & Trends Analysis Report By Treatment (Appetite Stimulants, Corticosteroids), By Type (Lung Cancer, Colorectal Cancer), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

암 악액질 시장 요약

세계의 암 악액질 시장 규모는 2024년에 25억 4,000만 달러로 추정되며, 2033년까지 39억 달러에 달할 것으로 예측됩니다.

2025-2033년 CAGR 4.86%로 성장할 것으로 예상됩니다. 암 발병률 증가, 악액질 환자 증가, 악액질의 임상적, 경제적 영향에 대한 인식이 높아지면서 시장을 주도하고 있습니다.

2023년 11월 미국 국립보건원(NIH)이 발표한 보고서에 따르면, 암 관련 악액질은 암 환자의 최대 74%에게 영향을 미친다고 합니다. 이는 암 사망의 20-30%를 직접적으로 유발하며, 22-30%에서 주요 사망 원인으로 작용하고 있습니다. 종양학에서 지지요법에 대한 관심이 높아지는 것도 시장 성장을 촉진하고 있습니다. 한편, 신흥시장에서의 의료비 증가와 암 치료 접근성 개선은 잠재 고객층 확대에 기여하고 있습니다. 전 세계적으로 암 진단 및 치료를 받는 환자가 증가함에 따라 악액질 관리의 필요성이 높아지고 있으며, 이는 암 악액질 산업의 성장을 견인할 것으로 예상됩니다.

자주 묻는 질문

  • 암 악액질 시장 규모는 어떻게 예측되나요?
  • 암 관련 악액질이 암 환자에게 미치는 영향은 무엇인가요?
  • 암 악액질 시장의 주요 성장 요인은 무엇인가요?
  • 암 악액질 시장에서 치료 방법은 어떤 것들이 있나요?
  • 암 악액질 시장의 주요 유통 채널은 무엇인가요?
  • 암 악액질 시장의 지역별 주요 포인트는 무엇인가요?
  • 암 악액질 시장에 참여하고 있는 주요 기업은 어디인가요?

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 암 악액질 시장 변수, 동향, 범위

  • 시장 계보 전망
    • 상부 시장 전망
    • 관련·부수 시장 전망
  • 시장 역학
  • 암 악액질 시장 분석 툴
    • 업계 분석 : Porter's Five Forces
    • PESTEL 분석
  • 암 악액질 시장 : 파이프라인 분석

제4장 암 악액질 시장 : 치료 추정·동향 분석

  • 암 악액질 시장 : 치료 변동 분석
  • 세계의 암 악액질 시장 규모와 동향 분석(치료별, 2021-2033년)
    • 식욕 증진제
    • 카나비노이드 수용체 작용제
    • 코르티코스테로이드
    • 동화·남성화 작용제
    • 기타

제5장 암 악액질 시장 : 유형 추정·동향 분석

  • 암 악액질 시장 : 유형 변동 분석
  • 세계의 암 악액질 시장 규모와 동향 분석(유형별, 2021-2033년)
    • 췌장암
    • 위암
    • 폐암
    • 대장암
    • 기타

제6장 암 악액질 시장 : 유통 채널 추정·동향 분석

  • 암 악액질 시장 : 유통 채널 변동 분석
  • 세계의 암 악액질 시장 규모와 동향 분석(유통 채널별, 2021-2033년)
    • 원내 약국
    • 소매 약국
    • 온라인 약국

제7장 암 악액질 시장 : 지역 추정·동향 분석

  • 지역별 시장 대시보드
  • 지역별 시장 점유율 분석(2024년 및 2033년)
  • 암 악액질 시장 : 지역별 : 주요 포인트
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 스웨덴
    • 덴마크
    • 노르웨이
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제8장 경쟁 구도

  • 주요 시장 진입 기업별 최근의 발전과 영향 분석
  • 기업/경쟁 분류
  • 벤더 상황
    • 주요 기업 히트맵 분석, 2024년
  • 기업 개요
    • AbbVie Inc.
    • Endo, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Abbott.
    • Nestle Health Science
    • Baxter.
    • Fresenius Kabi AG
    • Sandoz Group AG
    • Bristol-Myers Squibb Company
KSM

Cancer Cachexia Market Summary

The global cancer cachexia market size was estimated at USD 2.54 billion in 2024 and is projected to reach USD 3.90 billion by 2033, growing at a CAGR of 4.86% from 2025 to 2033. The rising cancer incidence and more patients with cachexia, and growing recognition of cachexia's clinical & economic impact, drive the market.

According to a report published by NIH in November 2023, Cancer-related cachexia affects up to 74% of cancer patients. It is directly responsible for 20-30% of cancer deaths, making it the main cause of death in 22-30% of cases. The increasing focus on supportive care in oncology is also driving market growth. However, increasing healthcare spending and improving access to cancer care in emerging markets are helping expand the potential customer base. As more patients receive cancer diagnoses and treatment worldwide, the need for cachexia management grows, which is expected to drive the growth of the cancer cachexia industry.

Global Cancer Cachexia Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cancer cachexia market report based on treatment, type, distribution channel, and region:

  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Appetite Stimulants
  • Cannabinoid Receptor Agonists
  • Corticosteroids
  • Anabolic/Androgenic Agents
  • Others
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Pancreatic Cancer
  • Gastric (Stomach) Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Type
    • 1.2.3. Distribution channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
    • 2.2.2. Type outlook
    • 2.2.3. Distribution channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Cancer Cachexia Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Cancer Cachexia Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Cancer Cachexia Market: Pipeline Analysis

Chapter 4. Cancer Cachexia Market: Treatment Estimates & Trend Analysis

  • 4.1. Treatment Segment Dashboard
  • 4.2. Cancer Cachexia Market: Treatment Movement Analysis
  • 4.3. Global Cancer Cachexia Market Size & Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
    • 4.3.1. Appetite stimulants
      • 4.3.1.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.3.2. Cannabinoid receptor agonists
      • 4.3.2.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.3.3. Corticosteroids
      • 4.3.3.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.3.4. Anabolic/androgenic agents
      • 4.3.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.3.5. Others
      • 4.3.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Cancer Cachexia Market: Type Estimates & Trend Analysis

  • 5.1. Type Segment Dashboard
  • 5.2. Cancer Cachexia Market: Type Movement Analysis
  • 5.3. Global Cancer Cachexia Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
    • 5.3.1. Pancreatic cancer
      • 5.3.1.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.3.2. Gastric (stomach) cancer
      • 5.3.2.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.3.3. Lung cancer
      • 5.3.3.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.3.4. Colorectal cancer
      • 5.3.4.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.3.5. Others
      • 5.3.5.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Cancer Cachexia Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Distribution Channel Segment Dashboard
  • 6.2. Cancer Cachexia Market: Distribution Channel Movement Analysis
  • 6.3. Global Cancer Cachexia Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
    • 6.3.1. Hospital Pharmacies
      • 6.3.1.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Retail Pharmacies
      • 6.3.2.1. Market estimates and forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Online Pharmacies
      • 6.3.3.1. Market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Cancer Cachexia Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2033
  • 7.3. Cancer Cachexia Market by Region: Key Takeaways
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Sweden
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Regulatory framework/ reimbursement structure
      • 7.5.7.3. Competitive scenario
      • 7.5.7.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Norway
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Regulatory framework/ reimbursement structure
      • 7.5.8.3. Competitive scenario
      • 7.5.8.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. China
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. India
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. Thailand
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Regulatory framework/ reimbursement structure
      • 7.8.4.3. Competitive scenario
      • 7.8.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. AbbVie Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Endo, Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Teva Pharmaceutical Industries Ltd.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Pfizer Inc.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Abbott.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Nestle Health Science
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Baxter.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Fresenius Kabi AG
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Sandoz Group AG
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Bristol-Myers Squibb Company
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제